February 4, 2005 -- On Friday, stocks ignored a disappointing report on job growth, focusing instead on uncharacteristically cheerful words from normally dour Fed Chairman Greenspan. As the day wore on, stocks built on their early strengths and closed near their highs. The Centient Biotech 200 gained a very strong 2.62%, rising 88.82 points to 3482.42, far outpacing the broad indexes. Threshold’s IPO was another poor showing, the third in the week for biotech, Martex announced a significant new contract, Novavax got a SARS research grant, OXiGENE likes the look of its anti-angiogenesis drug, and Repligen announced its earnings, or rather, the lack thereof. We give more details...
